exenatide and Cystic-Fibrosis

exenatide has been researched along with Cystic-Fibrosis* in 1 studies

Trials

1 trial(s) available for exenatide and Cystic-Fibrosis

ArticleYear
Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: A randomized crossover trial.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:3

    Impaired glucose tolerance (IGT) in cystic fibrosis (CF) manifests as postprandial hyperglycaemia. Pancreatic enzyme supplementation reduces the latter; restoring incretin secretion and slowing gastric emptying. We aimed to determine the acute effect of exenatide on postprandial glycaemia in young people with CF and IGT. Six participants with CF and IGT were studied on 2 days, in a double-blind randomized crossover trial. After overnight fasting, they received exenatide 2.5 mcg or placebo (0.9% saline) subcutaneously 15 minutes before a pancake meal labelled with

    Topics: Adolescent; Adult; Blood Glucose; Child; Cross-Over Studies; Cystic Fibrosis; Double-Blind Method; Exenatide; Female; Gastric Emptying; Glucose Intolerance; Humans; Hyperglycemia; Incretins; Male; Postprandial Period; Young Adult

2019